检索

期
标题
作者
卷 25, 编号 3 (2023)
Real-world experience with trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer and HER2-positive gastric cancer: A retrospective study
Evdokimov V., Bloshchinenko A., Abolmasov A., Vilensky A., Laskov M.
PDF
(Rus)
卷 25, 编号 1 (2023)
Following in the footsteps of SABCS 2022: top 12 advanced breast cancer studies that could change our clinical practice: A review
Kolyadina I.
PDF
(Rus)
卷 23, 编号 4 (2021)
Features of response to modern neoadjuvant chemotherapy with dual anti-HER2 blockade (trastuzumab and pertuzumab) in the patients with HER2-positive breast cancer stage II–III
Morozov D., Kolyadina I., Poddubnaya I., Ganshina I., Khokhlova S., Kоmetova V., Rodionov V.
PDF
(Rus)
卷 15, 编号 2 (2013)
Breast cancer: from guidelines to personalized oncology
PierFranco C., Valentina G.
卷 19, 编号 1 (2017)
Pharmacoeconomic aspects of biosimilars
Tryakin A., Rudakova A., Fogt S., Vaganov A., Tolkacheva D.
PDF
(Rus)
卷 18, 编号 2 (2016)
Bioequivalence assessment of BCD-022 (trastuzumab, manufactured by JSC BIOCAD, Russia) as compared with Herceptin® (F.Hoffmann-La Roche Ltd., Switzerland), used in combination with paclitaxel in HER2-positive metastatic breast cancer patients: findings of the international, double-blind phase III clinical study
Ignatova E., Burdaeva O., Kopp M., Kotiv B., Udovitsa D., Stroiakovskii D., Alekseev S., Sheveleva L., Khorinko A., Shapovalova I., Moiseenko V., Ivanov R.
PDF
(Rus)
卷 15, 编号 1 (2013)
Current approach to adjuvant therapy for breast cancer (a review)
Conte P., Guarneri V.
卷 17, 编号 4 (2015)
Neoadjuvant systemic therapy of HER2-positive breast cancer
Frolova M.
卷 17, 编号 2 (2015)
Brain metastases in her2-positive breast cancer: new opportunities for systemic therapy
Artamonova E., Manziuk L.
卷 16, 编号 4 (2014)
The effect of combinated treatment of a metastatic HER2-positive stomach cancer
Khvastunov R., Nenarokomov A., Tolstopiatov S., Babina K.
卷 16, 编号 3 (2014)
HER2-positive disseminated gastric and gastro-oesophageal junction adenocarcinoma: forecast, clinical course, treatment
Besova N.
卷 16, 编号 3 (2014)
Personalized approach to HER2-positive advanced breast cancertherapy
Stenina M.
卷 20, 编号 2 (2018)
Optimal duration of adjuvant trastuzumab therapy in patients with HER2-possitive early breast cancer: whether the problem is resolved?
Zhukova L., Ganshina I., Khatkova E., Tikhomirova T., Kondratyeva O.
PDF
(Rus)
卷 15, 编号 3 (2013)
Targetnaya terapiya metastaticheskogo raka zheludka: klinicheskiy opyt uspeshnogo lecheniya patsienta s retsidivom raka zheludka
Tlish E.
1 - 14 的 14 信息

检索提示:

  • 检索的名词区分大小写
  • 常用字词将被忽略
  • 默认情况下只有在查询结果满足所有检索词才返回（例如，隐含AND）
  • 使用OR结合多个检索词，便于查找含有这些检索词的文章，例如education OR research
  • 使用括号来创建更复杂的查询; 例如：archive ((journal OR conference) NOT theses)
  • 使用引号检索一个完整的词组; 例如： "open access publishing"
  • 使用-或者NOT排除一个检索词; 例如：online -politics or online NOT politics
  • 在检索词里使用 *作为通配符匹配任何字符序列; 例如., soci* morality 将符合含有 "sociological" or "societal"的词语

##common.cookie##